# A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

> **NCT06660173** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 409 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Maridebart Cafraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06660173
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2025-10-06
- **Final completion:** 2026-11-10
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660173, "A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06660173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*